5.1. Systemic Medications
Various oral medications with different mechanisms of action have been used to treat spasticity. The most commonly used medications include baclofen, tizanidine, dantrolene and benzodiazepines. Overall, these medications have marginal effect on focal spasticity (Simpson et al. 2009) and marginal to moderate effects on reducing segmental and generalized spasticity (Montane et al. 2004). In a systematic review on contemporary pharmacologic treatments for spasticity of the upper limb after stroke. Olvey et al. (2010) only found one study with a systemic drug (tizanidine) that reported significant reductions in upper limb spasticity after 16 weeks of treatment compared to placebo.
In a Cochrane review on pharmacological interventions other than botulinum toxin for spasticity after stroke, Lindsay et al. (2016) found seven RCTs with a total of 403 participants. Only two of them assessed a systemic drug versus placebo and only one with tizanidine showed significant results. Those two studies included 160 patients and in the meta-analysis of those the antispastic effect of the oral drugs on spasticity showed no significant effects (MAS, Odds Ratio for Response 1.66, 95% KI 0.21–13.07; n.s.). On the other hand, the authors identified a significant risk of adverse events per participant occurring in the treatment group versus placebo group (risk ratio (RR) 1.65, 95% CI 1.12 to 2.42; 160 participants; I2 = 0%).
The common adverse effects of oral drugs include dose-dependent adverse effects, such as drowsiness and tiredness. Therapeutic efficacy of these medications is only supported by a few placebo-controlled trials with inadequate sample size and lack of functional outcome measurements (Francisco and McGuire 2012; Winstein et al. 2016). Furthermore, likely attributed to these adverse effects or a reflection of limited efficacy, oral medications have poor adherence (Halpern et al. 2013). In general, it is recommended to limit the use of these oral medications for spasticity management (Francisco and McGuire 2012; Winstein et al. 2016). On the other hand, these oral medications as single drug or combination may be a cost-effective treatment option for those who can achieve adequate spasticity management without intolerable adverse effects.
Baclofen, a gamma amino butyric acid (GABA)-B agonist, is a potent inhibitory neurotransmitter. Baclofen has been shown dose-dependent reduction of spasticity and spasms, but has side effects of drowsiness and weakness. Abrupt discontinuation of baclofen may result in a withdrawal syndrome, characterized by rebound spasticity, hallucinations, and seizures (Medaer et al. 1991; Meythaler et al. 2004). Similar to baclofen, benzodiazepines modulate GABAergic transmission by binding GABA-A receptors. Similarly, abrupt discontinuation of benzodiazepines may result in a withdrawal syndrome. Concerns for its side effects, mainly drowsiness, sedation, reduced attention and memory impairment, and the potential for physiological dependence have limited the use of benzodiazepines as first-line treatment for spasticity. The use in post-stroke spasticity management is discouraged and might be reserved to situations when spasticity is accompanied by other conditions that are also amenable to benzodiazepine therapy, such as seizures, anxiety, insomnia, spasms, and other movement disorders (Medaer et al. 1991; Meythaler et al. 2004).
Tizanidine, a central alpha2-adrenergic receptor agonist, reduces spasticity and clonus via inhibiting the facilitatory ceruleospinal tracts and the release of excitatory neurotransmitters from spinal interneurons (Stevenson and Jarrett 2006). In addition to the typical side effects of oral spasmolytics, hepatotoxicity may also occur. Thus, monitoring liver function is important, especially in those patients who concomitantly take hepatically cleared drugs.
Unlike baclofen and tizanidine, dantrolene works directly on skeletal muscle by inhibiting the release of calcium from the sarcoplasmic reticulum during excitation–contraction coupling (Krause et al. 2004). Although it is peripherally acting, dantrolene has also been associated with side effects that appear to be centrally mediated, such as drowsiness, dizziness, fatigue, and weakness, perhaps through alteration of neuronal calcium homeostasis (Flewellen et al. 1983; Katrak et al. 1992). Due to its potential for hepatotoxicity, regular monitoring of liver function is recommended.
Beside baclofen, tizanidine, and dantrolene, other agents have reported to have some effects, including tolperison (Stamenova et al. 2005), gabapentin, clonidine, nabilone (Wissel et al. 2006), and cannabinoids (Whiting et al. 2015).
Summing up the results from studies on oral drugs in PSS, the evidence published from RCTs showed significant risk of side effects and no sufficient data to confirm that systemic antispastic drugs are effective in treating PSS.
Recommendations: Oral systemic medications can be used for segmental and generalized spasticity, but may be associated with dose-dependent adverse effects (level of evidence 2b, quality of evidence low, 0). Selection of type of oral medication depends on individual circumstances and may include combinations. These medications should be titrated slowly, and both clinical benefits and unwanted effects need to be monitored (level of evidence 1a, quality of evidence low, B+ [clinical reasoning]).
5.2. Botulinum Toxin Treatment
Botulinum toxin Type A (BoNT-A) is widely regarded as the treatment of choice for the medical management of focal and multi-focal signs and symptoms of the UMNS including but not limited to hypertonia, spastic dystonia, clonus, and spasms. Systematic studies have also demonstrated improvement in so-called passive function like reducing spasticity-associated pain, hygiene and passive movement of involved limbs, and reduction of mal-positioning of limbs (Brashear et al. 2002a, b) (level of evidence 1b). Demonstration of active functional gains in terms of enhancement of active limb movements in the upper limbs (e.g., reaching or grip and relieve movements with the hand) and increased mobility (e.g., gait speed and gait endurance) has proven to be difficult. But systematic reviews of the outcome of BoNT treatment in spastic upper limbs (Foley et al. 2013; Dong et al. 2017) (level of evidence 1a) and a randomized, controlled, trial in subjects with chronic PSS and traumatic brain injury–related spastic upper limb (Gracies et al. 2015) (level of evidence 1b) reported statistically significant functional improvements in active function of the upper limb.
Controlled studies in the post-acute phase of stroke rehabilitation (less than 3 months following stroke) showed that BoNT-A injected before spasticity became moderate or severe result in improvements in impairment and passive function and reduced occurrence of muscle and/or tendon shortening in long finger flexors (Hesse et al. 2012). The therapeutic outcomes also appeared to be more pronounced and longer lasting (Rosales et al. 2012; Fietzek et al. 2014) (level of evidence 1b). Thus, early BoNT-A intervention seems to have the potential to modify the natural evolution of PSS while a resent systematic review did not indicate higher functional gains or effects on disability (Rosales et al. 2016).
5.2.1. Treatment Outcomes: Upper Limbs
Numerous controlled studies and multiple meta-analyses show a dose-dependent effective reduction of spastic muscle tone, improvement in passive range of motion (PROM) and passive function (measured with the Disability Assessment Scale, DAS) as well as a reduction in carer burden while handling affected limbs, both by single and repeated intramuscular injections of BoNT-A (abobotulinumtoxinA, incobotulinumtoxinA, and onabotulinumtoxinA) in upper limb with increased spastic hypertonia in the chronic stage after stroke and other etiologies ((van Kuijk et al. 2002; Turkel et al. 2006), level of evidence 1a; (Simpson et al. 2008, 2016), level of evidence 1a; (Gracies et al. 2015), level of evidence 1b; (Dong et al. 2017), level of evidence 1a)). In severely affected arms, BoNT-A application supports self-care activities and integration of the spastic arm in everyday life by improving passive function (Baker and Pereira 2015) (level of evidence 1a). Evidence quality for the 11 studies for arm spasticity in a meta-analysis was moderate (GRADE). Significant results of BoNT-A therapy were observed for 4 to 12 weeks post-injection (SMD 0.80, 95% CI 0.55 to 1.06, P < 0.0001) and continued for up to 6 months (SMD 0.48, 95% CI 0.34 to 0.62, P < 0.0001). Randomized trials included in the systematic review showed a reduced incidence of shortening of finger muscles with improved hand hygiene (Hesse et al. 2012; Rosales et al. 2012) (level of evidence 1b).
In the subacute phase (<3 months) after stroke following BoNT-A use, forearm and leg spasticity significant reductions in velocity-dependent tone increase over more than 3 months could be documented in a systematic review with meta-analysis (3 studies), whereas no greater functional gains and no increase in side effects were shown (Rosales et al. 2016) (level of evidence 1a).
BoNT-A injections may improve active function in some of the patients with arm spasticity (Foley et al. 2013; Gracies et al. 2015; Baker and Pereira 2016, level of evidence 1a). Evidence quality for the six studies for effects on arm activities in a meta-analysis was low to very low (according to GRADE). A small significant result of BoNT-A therapy was documented 4 to 12 weeks post-injection (SMD 0.32, 95% CI 0.01 to 0.62, P = 0.04) and only for the Action Research Arm Test (ARAT)—persisted for up to 6 months (MD 1.87, 95% CI 0.53 to 3.21, P = 0.006). In a single randomized controlled trial of abobotulinumtoxinA, an increase in active finger and wrist extension with BoNT-A injections into the finger flexors was found and supported the prior statement (Gracies et al. 2015), (level of evidence 1b). For treatment of focal spasticity after stroke, BoNT-A is superior to oral antispastic medication (tizanidine) in terms of both efficacy, measured as reduction in muscle tone with the Modified Ashworth Scale, and adverse events (Simpson et al. 2009) (level of evidence 1b).
Recommendations: BoNT-A therapy should be considered for clinically relevant upper limb PSS that does not sufficiently respond to nonpharmacological treatment. In these cases, it should be entertained when the therapeutic goal is to support passive functions (prevention of contractures; hygiene, washing, dressing) (level of evidence 1a, quality of evidence moderate, B+) and can be used in selected cases to support active function (level of evidence 1a, quality of evidence low, 0).
5.2.2. Treatment Outcomes: Lower Limbs
In chronic ankle flexion spasticity with spastic pes equines and equinovarus gait pattern, significant reduction of muscle tone in the ankle following treatment with abobotulinumtoxinA and onabotulinumtoxinA by intramuscular injections into the calf muscle could be demonstrated after stroke (Pittock et al. 2003; Kaji et al. 2010; Wein et al. 2018) (level of evidence 1b) and after stroke and TBI (Gracies et al. 2017) (level of evidence 1b). Additionally a reduced use of gait tools (orthosis) and an improvement of the Clinical Global Impression Scale in gait were shown ((Pittock et al. 2003; Gracies et al. 2017; Wein et al. 2018), level of evidence 1b). However, no significant improvements in longitudinal gait parameters (e.g., gait speed and gait endurance) of the patients treated with BoNT-A could be achieved in that trials.
One systematic review (mainly by observational studies and case series, 14 studies, 181 patients) also shows a reduction of clonus activity in patients with chronic ankle flexion spasticity as an improvement in a different positive sign of the UMNS that velocity-dependent increase in muscle tone from BoNT treatment (Thanikachalam et al. 2017) (level of evidence 3a).
With respect to the treatment of hip and knee spasticity using BoNT-A injections (abobotulinumtoxinA, onabotulinumtoxinA, and incobotulinumtoxinA), clinical studies were able to show reduction of spastic movement disorders in hip and knee in the chronic stage of spasticity of different etiologies (stroke, traumatic brain injury, multiple sclerosis, and others), and it was also possible to conclude that interventions with BoNT-A showed improving mobility ((Hyman et al. 2000; Rosales and Chua-Yap 2008; Wissel et al. 2017), level of evidence 1b).
In an open dose-escalation study with incobotulinumtoxinA, dose escalation from 400 units to 600 units and 800 units showed increasing numbers of treated upper and lower limb muscles or spastic patterns (combinations of typical spastic muscle activation, e.g., spastic pes equines, pes varus, flexed elbow or wrist, and spastic fist) per escalation level and led to almost double the number of patients, who were able to walk independently without increasing the incidence of side effects at higher dose levels (Wissel et al. 2017) (level of evidence 2b).
Recommendations: BoNT-A therapy can be considered for clinically relevant lower limb PSS (ankle, knee, or hip) that does not sufficiently respond to nonpharmacological treatment (level of evidence 1b, quality of evidence moderate, 0 (functional benefit uncertain)). It is also an option to treat functionally relevant sustained clonus (level of evidence 3a, quality of evidence low, 0).
5.2.3. Treatment Outcomes: Spasticity- or Spasm-Associated Pain
Neuropathic (e.g., spontaneous burning pain in plegic limbs), nociceptive (e.g., knee joint pain when starting walking), spasm-related, and spasticity-associated (stretch- or exercise-induced muscle pain) pain following stroke are all part of the decision-making process with respect to selection of symptomatic treatment and treatments should be tailored accordingly (Finnerup 2017). Reduction of spasm-related and stretch- or exercise-induced spasticity-associated pain in spastic limb segments after injections of upper and lower extremity onabotulinumtoxinA in chronic spasticity was observed in a cohort study with 60 patients with mixed etiologies of spasticity in an open-label observational study and a randomized, placebo-controlled study in 273 patients following stroke and TBI ((Wissel et al. 2000, 2016), level of evidence 2b and 1b). Spasticity-associated stretch- or exercise-induced arm (Fheodoroff et al. 2017) or shoulder pain (Yelnik et al. 2007; Lim et al. 2008) also showed favorable influence by injections of abobotulinumtoxinA, incobotulinumtoxinA, and onabotulinumtoxinA (Fheodoroff et al. 2017, level of evidence 2b; Yelnik et al. 2007; Lim et al. 2008, level of evidence 1b).
Recommendations: BoNT-A therapy can be considered to treat spasm-related and stretch- or exercise-induced spasticity-associated pain in spastic limb segments, both in the upper or lower extremity (level of evidence 1b, quality of evidence low [partially indirect], 0).
5.2.4. Botulinum Toxin A Injection Guidance
It is believed that in order to improve the accuracy of BoNT injection, instrumented guidance using ultrasonography (US), electrical stimulation (ES), and electromyography (EMG) may be superior to a non-guided (e.g., pure anatomic localization) technique. Both ES and US appear to yield superior results over non-guided injection technique when BoNT is injected in wrist and finger flexors (Picelli et al. 2014; Santamato et al. 2014). ES (Chin et al. 2005; Picelli et al. 2012) and US (Picelli et al. 2012) have also been shown to be superior to anatomical guidance and EMG when injecting the triceps surae. A systematic review indicated that instrumented injection guidance is more effective than manual needle placement and showed similar effectiveness of US and ES for upper and lower limb spasticity in stroke (Grigoriu et al. 2015). A more recent investigation did not find a significant difference in clinical results among the various injection techniques when analyzing results of BoNT injections in a setting of an outpatient clinic (Zeuner et al. 2017). Thus, there is still no clear evidence that one injection technique is superior over another, but current literature suggests that for certain muscles instrument-guided injection is superior to pure anatomic localization (deep neck, forearm, and deep calf muscles).
Recommendation: Both US, ES, and EMG guidance can be used and are especially relevant when smaller or deeper muscles are injected (level of evidence 2a, quality of evidence low, 0). For the injection of larger superficial muscles, noninstrumented manual needle placement can be adequate (level of evidence 2a, quality of evidence low, 0).
5.2.5. BoNT-A Products
BoNT-A drugs available are different and not interchangeable. (BoNT-B is also commercially available, but will not be included in this review considering its limited clinical use and scarcity of studies in spasticity. While BoNT-C and BoNT-F have been tried in human studies are up to now exclusive to dystonia.) The currently available BoNT-A drugs in Europe and North America are: abobotulinumtoxinA (Dysport®; Ipsen Ltd., Slough, Berks, UK), incobotulinumtoxinA (Xeomin®; Merz Pharmaceuticals, Frankfurt/M, Germany), and onabotulinumtoxinA (Botox®; Allergan Inc., Irvine, CA, USA). A recent entry in the market, daxibotulinumtoxinA (Revance, USA) is currently being investigated in both dystonia and spasticity. Additional BoNT-A drugs used in other countries (South America, India, and Asia) to manage spastic hypertonia and movement disorders include the Chinese BoNT-A Hengli® (Lanzhou Institute of Biological Products, Lanzhou, Gansu Province, China) and marketed as Prosigne® elsewhere (e.g., Brazil). Neuronox® (Medy-Tox, Ochang, South Korea) is another BoNT-A available in some Asian countries. It is important to note that there has been no published systematic head-to-head comparison of the clinical properties, safety, and efficacy of commercially available formulations of BoNT-A. Hence, clinicians choose a BoNT-A formulation to treat PSS based on availability and experience with particular formulations, and no recommendation can be made regarding choice of a BoNT-A formulation in PSS.
5.2.6. BoNT-A Dosing
Appropriate dosing of BoNT-A is crucial in optimizing treatment outcomes and mitigating dose-related adverse events. Unfortunately, there is scarcity of dose-ranging studies (Simpson et al. 1996; Hyman et al. 2000; Gracies et al. 2015, 2017; Wissel et al. 2017) to allow evidence-based clinical decision-making with regard to dose selection for specific muscles. Hence, clinicians choose doses based on drug-specific summaries of product characteristic in package inserts, clinical experience, availability of toxins, and expert consensus recommendations ((Wissel et al. 2009; Esquenazi et al. 2013; Schramm et al. 2014), level of evidence 3).
Physician surveys suggest that many believe that greater flexibility in dosing might benefit some patients (Bensmail et al. 2014; Wissel 2018). Recently, a prospective, open-label, single-arm, multicenter, dose-titration study using high doses of incobotulinumtoxinA (up to 800 U) did not yield new safety signals (Wissel et al. 2017) (level of evidence 2b). In this particular trial, it was shown that high doses of incobotulinumtoxinA enabled simultaneous treatment of upper and lower limb and was associated with higher treatment goal attainment and no increase in side effect rate.
5.2.7. Adjuvant Therapies to BoNT-A
In a systematic review (without meta-analysis) of nine randomized trials (7 with neuromuscular electrostimulation, 2 with functional electrostimulation, 182 participants), it was shown that adjuvant electrostimulation therapy enhances the effect of BoNT-A injections on spasticity (Intiso et al. 2017) (level of evidence 1a). In two of these studies (both RCTs), spasticity was more responsive to additional electrostimulation after BoNT-A treatment than to additional stretching, but showed comparable effects as taping and lower effects than additional shock wave therapy. Neuromuscular electrostimulation was mostly performed in the studies for 30 min, 1 to 6 times a day for 3 to 5 days after the injection. In another systematic review, 17 studies were included; it was shown that the effect of BoNT-A injections could be improved by various adjuvant therapies (Mills et al. 2016). Thus, an added benefit in the sense of a stronger tonus reduction (MAS ≥1) was demonstrated to be proven for concomitant physiotherapy, modified constraint-induced movement therapy (mCIMT), electrostimulation, casting and dynamic splint treatment compared to BoNT-A alone, but not for taping, segmental muscle vibration, cyclic functional electrostimulation, or motorized arm ergometer (Mills et al. 2016) (level of evidence 1a).
Individual examples from selected studies are: After BoNT-A treatment of spastic calf muscles, a 1-week casting and to a lesser extent a 1-week taping showed better results with regard to spasticity reduction, increase of passive range of motion, and increased walking distance per time (6 min walking test) for 3 months after inclusion compared to a 1-week manual stretching by a physiotherapist following injection of BoNT-A (Carda et al. 2011) (level of evidence 1b). In another randomized controlled study for spastic pes equinus, no relevant additional effect of taping could be demonstrated (Karadag-Saygi et al. 2010) (level of evidence 1b).
In a Cochrane review, limited evidence could be provided as to whether and how multi-professional rehabilitation after BoNT-A treatment could improve spasticity in patients following stroke (3 RCS with 91 participants after stroke; (Demetrios et al. 2013), level of evidence 1a). With low-quality studies (GRADE) for mCIMT treatment following BoNT-A treatment, an improvement in active motor function and spasticity reduction could be shown. With very low-quality studies (GRADE) for occupational therapy following BoNT-A treatment improved in elbow mobility using a dynamic elbow extension splint compared to ergotherapy alone could be shown.
Recommendations: Neuromuscular electrostimulation applied for 3 to 5 days after BoNT-A therapy can be considered to enhance treatment effects in treated muscle groups (level of evidence 1a, quality of evidence low (risk of bias), 0). Safety aspects for the medical products used need to be taken into account. Other adjuvant therapies such as casting taping, mCIMT, and dynamic splint treatment can be used as individually indicated (level of evidence 1a, quality of evidence very low (risk of bias, inconsistency), 0). Active motor training and robotic training should be tailored to individual goals (refer to chapters on arm rehabilitation and mobility).
5.3. Neurolysis
Nerve blocks with neurolytic agents (phenol and alcohol) are effective in managing focal spasticity (Petrillo and Knoploch 1988; Chua and Kong 2000; Karri et al. 2017). For neurolysis, concentration of phenol usually ranges for 5% to 7%, while concentration of alcohol varies from 50% to 100%. These agents denature proteins in axons and membranes nonselectively in both afferent and efferent nerve fibers, leading to denervation and degeneration of spindles (Bodine-Fowler et al. 1996). Therefore, it requires precise localization and injection of these agents to the nerve fibers at the trunk, branch, or motor points of the target nerves. Precision localization is usually achieved with guidance of ultrasound imaging and/or electrical stimulation (Karri et al. 2017). Neurolysis usually produce immediate anesthesic effects and a later neurolytic effect on spasticity reduction. The duration depends on the dose, accuracy of injection, and repeated injections, ranging from 3 to 9 months. Unlike BoNT-A injections, nerve blocks can be repeated as early as several days. Common adverse effects include post-injection dysesthesia, localized swelling, and excessive weakness. In a recent retrospective chart review of 293 procedures, phenol neurolysis has a relatively favorable safety profile, including pain (4.0%), swelling and inflammation (2.7%), dysesthesia (0.7%), and hypotension (0.7%) (Karri et al. 2017). Although nerve blocks are widely used to manage spasticity, there is paucity of evidence of efficacy and safety based on randomized controlled studies. In a randomized, double-blind trial which compared phenol neurolysis and BoNT-A injection in the treatment of ankle and foot spasticity after stroke (Kirazli et al. 1998), the authors reported that both interventions were effective in plantar flexor spasticity reduction. The benefits were more significant in the BoNT-A group at weeks 2 and 4 post-injection, while there was no significant difference between two interventions at weeks 8 and 12.
Recommendations: Phenol and alcohol neurolysis can be considered for clinically relevant PSS that does not sufficiently respond to nonpharmacological treatment (and oral medication), especially when BoNT-A treatment is not feasible (level of evidence 2b, quality of evidence low, 0). The possibility of long-term unwanted side effects, especially neuropathic pain following mixed nerve injections, need to be taken into account.
5.4. Intrathecal Baclofen (ITB)
Intrathecal baclofen therapy (ITB) is effective in managing post-stoke spastic hypertonia (Meythaler et al. 2001; Ivanhoe et al. 2006). It is licensed in the European Union to manage severe chronic spasticity in children between ages 4 and 18 years that is recalcitrant to oral spasmolytics and for managing severe spasticity of both cerebral and spinal etiology. In the United States (US), ITB is approved by the US Food and Drug Administration (US FDA) for managing severe spasticity of both cerebral and spinal etiology. Although few randomized, controlled trials of safety and efficacy exist, ITB has high levels of satisfaction among users of 10–24 years’ duration (Mathur et al. 2014).
The US FDA recommends initiation of ITB therapy 1-year after disease onset, but a consensus panel of ITB experts suggested that ITB can be considered as early as 3–6 months post-stroke when spasticity is not controlled by other modalities or a patient is unable to tolerate side effects of other treatments (Francisco et al. 2006). A more recent consensus panel of experts (Saulino et al. 2016) recommended early consideration of ITB to avoid or delay various complications of spasticity and mitigate subsequent functional impairments. The same group commented that ITB should be considered only if other treatments have failed.
Meythaler et al. (2001) demonstrated superiority of ITB over placebo in a small cohort of stroke patients. Twenty-one stroke survivors with severe spasticity received either baclofen or placebo intrathecally. At 6 h post-bolus infusion, the average (mean ± SD) paretic lower limb Ashworth scores of the group that received baclofen decreased significantly from 3.3 ± 1.2 to 1.4 ± 0.7 (P < 0.0001), spasm score from 1.2 ± 1.2 to 0.1 ± 0.3 (P = 0.0224), and reflex score from 2.1 ± 1.2 to 0.1 ± 0.5 (P < 0.0001), compared to the group that received placebo. Seventeen subjects then received an intrathecal pump for continuous baclofen infusion. At 12 months following implantation and with an average daily dose of 268 micrograms per day, the average lower limb Ashworth score of the paretic side decreased from 3.7 ± 1.0 to 1.8 ± 1.1 (P < 0.0001), the spasm score decreased from 1.2 ± 1.3 to 0.6 ± 1.0 (P = 0.4282), and the reflex score decreased from 2.4 ± 1.3 to 1.0 ± 1.3 (P < 0.0001).
The effect of ITB on ambulant stroke survivors is controversial. Small reports (Francisco and Boake 2003; Remy-Neris et al. 2003) showed improvement in gait speed following ITB therapy, but others demonstrated otherwise (Kofler et al. 2009).
A recent randomized, controlled, open-label, multicenter trial also demonstrated superiority of ITB therapy over conventional medical management (cMM) with oral spasmolytics in terms of efficacy (mean Ashworth scale score reduction, −0.99 (ITB) vs. −0.43 (cMM); Hodges-Lehmann estimate −0.667 (95.1% CI −1.0000 to −0.1667); p = 0.0140) and pain control (numbers). While more subjects who received ITB reported adverse events (24/25 patients, 96%; 149 events) compared to those who received cMM (22/35, 63%; 77 events), no new safety signals were discovered (Creamer et al. 2018a, b).
Recommendations: ITB can be considered for clinically relevant severe segmental or generalized PSS that does not sufficiently respond to other interventions (level of evidence 1b, quality of evidence moderate, 0 (benefit risk for harm assessment)). ITB treatment ought to be tested, initiated, adjusted, and monitored with long-term support (including emergency work-up when indicated) by physicians experienced with the treatment (level of evidence 1b, quality of evidence moderate, A+ (benefit risk for harm assessment)).
5.5. Surgical Management
Surgical procedures at the spinal cord level, such as interventions in the posterior root entry zone or dorsal rhizotomy, may be introduced in severe cases of spasticity after stroke, which are otherwise untreatable and represent a possibility of avoiding abnormal positions due to a severe spasticity and its complications in care, hygiene, pain, and contractures (review by (Chambers 1997), level of evidence 3a). One positive case report with persistent effects for the partial posterior rhizotomy is available in the literature ((Fukuhara and Kamata 2004), level of evidence 4). Controlled studies on these procedures in children with cerebral palsy are published, and studies in adults following stroke are not available. One major criticism with this surgical procedure is that it may only bring temporal improvements.
Partial neurotomy of the motor branches of the tibial nerve to the triceps surae muscle is an established neurosurgical procedure and leads to reduced spastic muscle tone in pes equinus or equinovarus deformity, and therefore can improve positioning of the foot and can reduce associated pain during walking ((Sindou and Mertens 2000), level of evidence 2b).
Following reports of successful orthopedic surgery with fasciotomy, transfer of muscle attachments, tendon transfer, and even bony surgery to increase upper and lower limb function in persons with low functioning spastic upper and lower limbs following spinal cord injury (Fox et al. 2018) (level of evidence 3) in the last 10 years also in chronic stroke patients with limited upper and lower limb function, those procedures became more available, but no large cohort studies are published. Fascia, tendon and muscle lengthening (e.g., Achilles tendon lengthening, soleus muscle fasciotomy, or lengthening), and tendon transfer surgery (e.g., transfer of the tendon of the flexor carpi ulnaris muscle to the dorsal aspect of the wrist or tibialis posterior split transfer and transpositioning of a part of the tendon to the dorsal aspect of the foot) may help correcting spastic hand or foot posture and help to improve active wrist and foot extension to improve residual function as well as preventing complications due to spastic posturing and development of contracture ((Duquette and Adkinson 2018), level of evidence 4; (Sturbois-Nachef et al. 2019), level of evidence 3). Despite the recognized effectiveness of orthopedic surgery for neuro-orthopedic disorders like chronic stroke patients with spastic contractures, few studies have formally evaluated them. Hence, there is a need for research to provide evidence to support orthopedic surgery for treating such neuro-orthopedic disorders (Genet et al. 2018).
Thumb-in-palm deformity is a well-known cause of disability in the chronic stroke population with upper limb spasticity but no reports on surgical treatments are published. On the other hand, surgical correction of spastic flexion of the thumb due to in juvenile cerebral palsy is established and it was evaluated in a Cochrane review. The authors describe a positive effect noted by patients (patient-related outcome) and the surgeons. The authors of the review critiqued that no standardized surgical procedure is defined, and different assessment methods in evaluation of the results following surgery were used. The authors concluded that based on the data available an evidence-based assessment of this treatment, procedure was not possible (Smeulders et al. 2005) (level of evidence 1a).
Recommendations: In individual cases, after careful examination in the multi-professional team and exhaustion of other reversible treatment options for spastic movement disorder, surgical procedures may be considered as treatment option in chronic spastic movement disorder following stroke (level of evidence 4, quality of evidence very low, 0).
1